Search for: "Acy v. State"
Results 1 - 20
of 114
Sorted by Relevance
|
Sort by Date
30 May 2021, 9:51 pm
ACI faculty will offer presentations on the following topics: • Regulatory and Legislative Developments Impacting the Biopharmaceutical Industry • The Impact of Amgen v Sanofi on In-House Patenting Strategies • The "Skinny Label" Post-GSK v Teva regarding Biosimilar Carve-Outs • Litigation Strategies for Challenging Reference Drug Patents in IPRs • APJs speaking on Practice, Policy, and Procedure • A "Think Tank" on… [read post]
2 May 2015, 9:24 pm
Amgen and Celltrion v. [read post]
11 Apr 2014, 9:42 pm
ACI faculty will help attendees: • Understand the battles over naming and substitution on the federal and state levels and exploring the implications on competition including the FTC's current perspective; • Analyzing the arguments in the first BPCIA case, Sandoz Inc. v. [read post]
19 Aug 2017, 8:06 pm
ACI faculty will provide insights into: • The impact of TC Heartland on jurisdiction and venue • The legal and business repercussions of Helsinn • Sandoz v. [read post]
25 Aug 2018, 9:09 pm
ACI faculty will help attendees in: • Understanding the connection between drug pricing and drug patents; • Examining how different jurisdictions are interpreting the TC Heartland decision for pharmaceutical patent infringement filings; • Analyzing the significance of the Federal Circuit's Allegan Inc. v. [read post]
15 Aug 2018, 7:51 pm
In State v. [read post]
18 Sep 2021, 8:38 pm
" ACI faculty will give presentations on: • GSK v. [read post]
14 Mar 2022, 8:43 am
Take, for example, the District Court of Utah’s March 3rd opinion in ACI Payments, Inc. v. [read post]
14 Nov 2011, 11:59 am
Dukes and AT&T Mobility v. [read post]
29 Nov 2010, 7:54 pm
Supreme Court oral argument in Wall v. [read post]
23 Sep 2013, 12:13 pm
Jude Medical v. [read post]
25 Feb 2011, 9:28 pm
The conference will allow attendees to: • Decipher the proposed revision to the standard of invalidity under Microsoft v. i4i; • Assess the evolving state of the law on double patenting type obviousness; • Analyze the significance of the Supreme Court's grant of certiorari in Global Tech v. [read post]
20 Mar 2009, 4:04 am
Last week, in State v. [read post]
10 Dec 2008, 6:33 pm
In Wyeth v. [read post]
6 Jun 2010, 5:22 pm
The court’s 4-0 decision (the newest justice, Gilbert V. [read post]
13 Sep 2013, 7:17 am
” Pfizer, Inc. v. [read post]
27 Jun 2011, 6:56 pm
("ACI") appeals from the final judgment of the United States District Court for the Southern District of California. [read post]
17 Jul 2008, 7:27 pm
See Adkins v. [read post]
22 May 2014, 3:58 pm
The agenda includes the following presentations: Minimizing the Uncertainty Surrounding the Untested Pathway: Insight Into FDA's Current Position and Initiatives Regarding Biosimilars Predicting Follow-On Entry and Evaluating the Risk and Commercial Opportunity in the Emerging Biosimilar Landscape New Kid No More: Evolution in Biosimilars Science and Regulations The Holy Grail for Biosimilars: Meeting FDA's Requirements for Biosimilarity and the Heightened Standard of Interchangeability… [read post]
13 Sep 2015, 8:13 am
The panelists also debated the meaning of the district court’s holding in U.S. v. [read post]
